Dendreon Provenge DNDN Share Trading Increases!

Following the announcement that the FDA approved the first active immune-booster Provenge, the stocks of Dendreon (DNDN) skyrocketed until they reached a halt at $45.50.  Well now, we have news that share trading has DNDN increased to  $53.50, another big jump.

“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” Karen Midthun, acting head of the FDA biologics center, said in a statement.

DNDN is right now a hot share in the Internet share trading sites.  We’ll keep a watch on the evolution of this and will bring you more updates.